- Home
- PRVA vs CELC Comparison
PRVA vs CELC Comparison
Compare PRVA & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRVA | CELC |
|---|---|---|
| Founded | 2007 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.1B |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | PRVA | CELC |
|---|---|---|
| Price | $23.33 | $111.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 8 |
| Target Price | $30.50 | ★ $100.13 |
| AVG Volume (30 Days) | 726.0K | ★ 771.6K |
| Earning Date | 02-26-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.88 | N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $2,042,569,000.00 | N/A |
| Revenue This Year | $23.19 | N/A |
| Revenue Next Year | $13.74 | N/A |
| P/E Ratio | $167.12 | ★ N/A |
| Revenue Growth | ★ 19.01 | N/A |
| 52 Week Low | $18.77 | $7.58 |
| 52 Week High | $26.51 | $120.32 |
Technical Indicators
Market Signals| Indicator | PRVA | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 48.52 | 58.26 |
| Support Level | $22.40 | $105.02 |
| Resistance Level | $23.70 | $120.32 |
| Average True Range (ATR) | 0.77 | 6.35 |
| MACD | 0.00 | -0.13 |
| Stochastic Oscillator | 56.82 | 59.86 |
Price Performance
Historical ComparisonAbout PRVA Privia Health Group Inc.
Privia Health Group Inc is a technology-driven, national physician-enablement company. It collaborates with medical groups, health plans, and health systems to optimize physician practices, improve patient experiences, and reward doctors for delivering high-value care in both in-person and virtual care settings.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.